Trial Profile
A Study to Evaluate the Feasibility of HER2-Directed Targeted Therapy in Patients With Heavily Pretreated HER2-Negative Metastatic Breast Cancer With Elevated Serum Levels of The Soluble HER2 Extracellular Domain and/or HER2-Overexpressing Circulating Tumor Cells
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2016
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Feb 2016 New trial record
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium